Petosemtamab

4 trials 4 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

4 Recruiting

0 Completed trials

1 Sponsors

14 Countries

Phase III

Phase II

Phase I (FiH)

Phase III: 2 Phase II: 1 Phase I (FiH): 1

Oversight events:

1 serious breach 1 corrective measure across 2 trials

View oversight register →

Indications tested

Colorectal cancer metastatic 1 Non-small cell lung cancer 1

Sponsors using this IMP

All trials

4 total

A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC Recruiting

2025-522867-13-00 Phase II 6 countries Merus B.V.
A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting

2023-510322-32-00 Phase III 12 countries Merus N.V.
A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting

2023-510323-30-00 Phase III 14 countries Merus B.V.
Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid … Recruiting

2024-513627-16-01 Phase I (FiH) 5 countries Merus B.V.

Showing 1–4 of 4 trials

← All drugs A–Z